<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00407147</url>
  </required_header>
  <id_info>
    <org_study_id>ProBac</org_study_id>
    <nct_id>NCT00407147</nct_id>
  </id_info>
  <brief_title>Procalcitonin Level to Discontinue Antibiotics on ICU Patients With no Obvious Site of Infection</brief_title>
  <official_title>ProBac - Use of Procalcitonin Level as Part of a Decision Tree to Discontinue Antibiotics When Started Empirically in the ICU in Hemodynamically Stable Patients With no Site of Infection Identified</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Brahms AG</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Brahms AG</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to test whether a U.S. Food and Drug Administration (FDA)
      approved laboratory test (PCT Kryptor) can help doctors make better decisions on the need for
      antibiotic therapy in ICU patients with suspected infections.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The study is undertaken as prospective, randomized, controlled, multicenter trial. The study
      population, ICU patients with empiric antibiotic treatment due to suspected but unproven
      infection, is randomly assigned to either a Standard Care Group or a Procalcitonin (PCT)
      Guided Group. In the standard care group, antibiotic treatment would be based totally on
      clinical decision making with &quot;traditional thought processes&quot; (i.e., cultures, response to
      antibiotics, risk of untreated infection, other laboratory findings, etc.). The PCT guided
      group will use the same &quot;traditional thought processes&quot; and in addition the physician will be
      given access to a PCT value for Day 1 and Day 4 along with the recommended thresholds for
      likelihood of infection. In conjunction with other laboratory findings and clinical
      assessments the threshold of PCT is used to continue or discontinue empiric antibiotic
      treatment.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    termination due to futility (very slow patient enrollment)
  </why_stopped>
  <start_date>July 2008</start_date>
  <completion_date type="Actual">June 2009</completion_date>
  <primary_completion_date type="Actual">June 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Days on antibiotics beginning with day 4 until the first day without antibiotics (up to max. 28 days follow up)</measure>
    <time_frame>28 days</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Days on antibiotics during ICU stay</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sepsis classification</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>SOFA score (modified)</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU or hospital mortality up to 28 days</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of infections</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU and hospital length of stay</measure>
    <time_frame>up to 28 days</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Infection</condition>
  <condition>Bacterial Infection</condition>
  <condition>Sepsis</condition>
  <arm_group>
    <arm_group_label>Control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Standard treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>PCT</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PCT guided arm</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Procalcitonin assay - B.R.A.H.M.S PCT sensitive Kryptor</intervention_name>
    <description>antibiotic treatment based on clinical decision making with &quot;traditional thought processes&quot; used in both groups. In addition the physician will be given access to Procalcitonin values with recommended thresholds for likelihood of infection.</description>
    <arm_group_label>PCT</arm_group_label>
    <other_name>B.R.A.H.M.S, Kryptor, Procalcitonin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Suspected infection (no clear-cut source of infection) as defined by the treating
             physician

          -  Empiric antibiotic treatment

          -  No clear-cut source of infection by clinical or microbiological criteria

          -  ICU patient

          -  Informed consent

        Exclusion Criteria:

          -  Age &lt;18 years

          -  Pregnancy

          -  Hemodynamic instability defined as persistent hypotension, need for on-going
             aggressive resuscitation and/or vasopressor support to maintain an adequate mean
             arterial blood pressure

          -  Need for antibiotic prophylaxis

          -  Patient withdrawn from empiric antibiotic treatment before Day 4

          -  Severely immuno-compromised patient (liver cirrhosis (Child-Pugh class C),
             immunosuppressive drugs after transplantation, neutropenia (absolute neutrophil count
             &lt;1000 counts/L), CD-4 count less than 200)

          -  Patient with suspected bacterial or fungal endocarditis

          -  Patient with suspected meningitis

          -  Cardiopulmonary bypass within the last 7 days1)

          -  Major surgery within the last 7 days (surgery that induces a major inflammatory
             response such as heart or aortic surgery or major abdominal surgery (i.e.
             duodenopancreatectomy) or any surgery requiring massive blood transfusion.)

          -  Multiple trauma within the last 7 days

          -  Cardiopulmonary resuscitation (CPR) within the last 7 days

          -  Burns &gt;20% body surface area

          -  Patient in terminal status referred for palliative care

          -  Patient with advanced directives or Do Not Resuscitate (DNR) orders

          -  Patient who is already enrolled in another therapeutic clinical study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Phil Dellinger, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>The Cooper Health System</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Saint Louis University - medical intensive care unit</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cooper University Hospital</name>
      <address>
        <city>Camden</city>
        <state>New Jersey</state>
        <zip>08103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Rhode Island Hospital</name>
      <address>
        <city>Providence</city>
        <state>Rhode Island</state>
        <zip>02903</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Germany</country>
  </removed_countries>
  <reference>
    <citation>Vincent JL, Bihari DJ, Suter PM, Bruining HA, White J, Nicolas-Chanoin MH, Wolff M, Spencer RC, Hemmer M. The prevalence of nosocomial infection in intensive care units in Europe. Results of the European Prevalence of Infection in Intensive Care (EPIC) Study. EPIC International Advisory Committee. JAMA. 1995 Aug 23-30;274(8):639-44.</citation>
    <PMID>7637145</PMID>
  </reference>
  <reference>
    <citation>Garnacho-Montero J, Garcia-Garmendia JL, Barrero-Almodovar A, Jimenez-Jimenez FJ, Perez-Paredes C, Ortiz-Leyba C. Impact of adequate empirical antibiotic therapy on the outcome of patients admitted to the intensive care unit with sepsis. Crit Care Med. 2003 Dec;31(12):2742-51.</citation>
    <PMID>14668610</PMID>
  </reference>
  <reference>
    <citation>Christ-Crain M, Jaccard-Stolz D, Bingisser R, Gencay MM, Huber PR, Tamm M, Müller B. Effect of procalcitonin-guided treatment on antibiotic use and outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet. 2004 Feb 21;363(9409):600-7.</citation>
    <PMID>14987884</PMID>
  </reference>
  <reference>
    <citation>Rau B, Steinbach G, Gansauge F, Mayer JM, Grünert A, Beger HG. The potential role of procalcitonin and interleukin 8 in the prediction of infected necrosis in acute pancreatitis. Gut. 1997 Dec;41(6):832-40.</citation>
    <PMID>9462219</PMID>
  </reference>
  <reference>
    <citation>Meisner M, Tschaikowsky K, Palmaers T, Schmidt J. Comparison of procalcitonin (PCT) and C-reactive protein (CRP) plasma concentrations at different SOFA scores during the course of sepsis and MODS. Crit Care. 1999;3(1):45-50.</citation>
    <PMID>11056723</PMID>
  </reference>
  <reference>
    <citation>Bergmans DC, Bonten MJ, Gaillard CA, van Tiel FH, van der Geest S, de Leeuw PW, Stobberingh EE. Indications for antibiotic use in ICU patients: a one-year prospective surveillance. J Antimicrob Chemother. 1997 Apr;39(4):527-35.</citation>
    <PMID>9145828</PMID>
  </reference>
  <reference>
    <citation>Røder BL, Nielsen SL, Magnussen P, Engquist A, Frimodt-Møller N. Antibiotic usage in an intensive care unit in a Danish university hospital. J Antimicrob Chemother. 1993 Oct;32(4):633-42.</citation>
    <PMID>8288506</PMID>
  </reference>
  <reference>
    <citation>Knaus WA, Draper EA, Wagner DP, Zimmerman JE. APACHE II: a severity of disease classification system. Crit Care Med. 1985 Oct;13(10):818-29.</citation>
    <PMID>3928249</PMID>
  </reference>
  <verification_date>January 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 29, 2006</study_first_submitted>
  <study_first_submitted_qc>November 29, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 4, 2006</study_first_posted>
  <last_update_submitted>January 16, 2012</last_update_submitted>
  <last_update_submitted_qc>January 16, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">January 18, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>bacterial infection</keyword>
  <keyword>empiric antibiotic treatment</keyword>
  <keyword>duration antibiotic treatment</keyword>
  <keyword>reduce antibiotic treatment</keyword>
  <keyword>procalcitonin</keyword>
  <keyword>PCT Kryptor</keyword>
  <keyword>sepsis</keyword>
  <keyword>Intensive Care Unit</keyword>
  <keyword>antibiotic treatment</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Bacterial Infections</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
    <mesh_term>Antibiotics, Antitubercular</mesh_term>
    <mesh_term>Calcitonin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

